Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
Portfolio Pulse from Lara Goldstein
UK-based Small Pharma (OTCQB:DMTTF) reported a 30% quarterly cash outflow, with cash on hand as of May 31, 2023, at approximately $9.9 million. The company expects its operational restructuring to reduce cash burn in upcoming quarters. Small Pharma's DMT assets SPL026 and SPL028 are undergoing clinical trials, with combined data potentially enabling an expedited path for a multi-site Phase 2 study for SPL028 in 2024. The company's IP portfolio has grown significantly, with 26 patents granted and 95 applications pending.
July 28, 2023 | 8:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Small Pharma reported a 30% quarterly cash outflow, but expects operational restructuring to reduce cash burn. The company's DMT assets SPL026 and SPL028 are undergoing clinical trials, with potential for an expedited Phase 2 study in 2024.
Small Pharma's financial results show a significant cash outflow, which could be a concern for investors. However, the company's operational restructuring is expected to reduce cash burn, which could improve its financial position. Additionally, the ongoing clinical trials for its DMT assets and the potential for an expedited Phase 2 study could be positive for the company's future prospects.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100